IL6 and endometriosis: In endometriosis, the IL-6 pathway has long been implicated as a central driver of fibrotic pathology [71–73], with more recent studies identifying persistent activation of STAT3 via IL-6 trans-signaling as a driving mechanism, and highlighting IL-6 inhibition as a potential therapeutic intervention [74].